cosjobs
Footballguy
This was a great close and after-market for TVIX owners. Glad I was buying all the way down to 133. Sold back 10% of my holding for 185 after hours. Lots still in the tank for a run to 900
Last edited by a moderator:
Fantasy Football - Footballguys Forums
This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
Stock Thread (14 Viewers)
- Thread starter St. Louis Bob
- Start date
kevzilla
Footballguy
cosjobs
Footballguy
Yeah, I remember reading about when Soros was bankrolling a basement pizza joint for pedophiles.
Bossman
Footballguy
Lesson #21
Selling Puts; Limiting Risk; Lower your strike price
So you're interested in Bossmans Put selling scheme but you're not comfortable with such risk.
Today NERV 6/19 $5 puts are selling at $1.30 ... while the stock price is mid $12 right now
Sell 20 $5 puts, ties up $10k in margin (2000 shares x the $5 strike price)
Premium pays you $2600 (2000 x $1.30)
but $10k ... that's a lot of Benjamins on the line. Palms are all sweaty and junk now ...
Breathe ... the money is still in your account. It stays there until the chance the stocks are put to you.
The only way you lose in THIS case would be if the stock falls BELOW $3.70 ($5 strike less $1.30 premium you were paid) in the next 4 weeks (6/19 expiration).
A $12 stock ... falling below $3.70 in 4 weeks. Let that sink in. When was the last time NERV was selling below $3.70 a share? ... that answer would be NEVER.
Now what are the chances that it falls to say $3? ..... If it did, you lose $1400 (2000 x $0.70) 5% chance? ... lets be conservative and say a 10% chance ...
Ask yourself ... are you afraid of a 10% chance to lose $1400?... with the more likely, 90% scenario you keep your $2600 premium?
If you don't have $10k to tie up ... sell 10 $5 puts at $5k margin.
Please be careful. This is real money and I am very very far from being an expert. I'm only using my common sense ...
... and my common sense tells me that selling $5 NERV puts is free money.
cosjobs
Footballguy
Are you watching the after-hours action? Its been bouncing $10-15 above close. I'm petty excited for the pre-market, If this holds tonight, it could get to 200 tomorrow morning, before the open.(or go to 140 with horrible unemployment number updates)
cosjobs
Footballguy
Hopefully my readers will remember when I chided someone for selling at the dip from the 130s to the 120s, on the way down to 133. This afternoon- 133 -185. This is one frisky harlot.Now officially pimping for that whore
Last edited by a moderator:
Binky The Doormat
Footballguy
Last edited by a moderator:
FreeBaGeL
Footballguy
I think NERV was one hell of a find, @Bossman. Those premiums are insane.
It would be one thing if this were a 0.40 cent stock that ran up to $13 on some newsetter push or something. But even on its worst days this is a stock that trades in the $4-$8 range. And typically the low end of that range has come from either bad earnings or a pessimistic run up to earnings, but we are already past earnings this time around and have no more earnings calls prior to expiry.
These are the types of $5 put premiums I would expect to see on a volatile stock currently trading at $6-$7. Heck even for that they would be kind of high. But a stock trading at $12? Crazy.
I took a position not as large as yours, but decently sized.
It would be one thing if this were a 0.40 cent stock that ran up to $13 on some newsetter push or something. But even on its worst days this is a stock that trades in the $4-$8 range. And typically the low end of that range has come from either bad earnings or a pessimistic run up to earnings, but we are already past earnings this time around and have no more earnings calls prior to expiry.
These are the types of $5 put premiums I would expect to see on a volatile stock currently trading at $6-$7. Heck even for that they would be kind of high. But a stock trading at $12? Crazy.
I took a position not as large as yours, but decently sized.
Last edited by a moderator:
Don Hutson
Footballguy
Umang is a Texas doctor who has been promoting leronlimab almost daily on his twitter page.
Bob Sacamano
Footballguy
FreeBaGeL
Footballguy
Weird point he's making anyway. In that graph it only every worked as support, not resistance. The one time it was tested for resistance it busted right through it like it wasn't even there.
Not the graph, the gif of Powell. They are voting on another free $1200 for everyone on Friday. Printing off 3 big beautiful Trillion $ coins to cover it.
Last edited by a moderator:
fruity pebbles
Footballguy
cosjobs
Footballguy
Last edited by a moderator:
cosjobs
Footballguy
From the Pharmacy Times
Novel Drug May Reduce Inflammation in Critical COVID-19 Patients
2020-05-12 13:39:00
Jill Murphy, Assistant Editor
A pre-print version of a manuscript about the development of leronlimab describes the immunological mechanism by which leronlimab restores immune function and impacts the coronavirus disease 2019 (COVID-19), according to a CytoDen press release.
The manuscript, entitled “Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19,” has been submitted for publication and is currently under peer review.
The pre-print describes a cohort of 10 critically ill patients after treatment with leronlimab who experienced reversed hyper immune activation and inflammation, as well as reversed immunosuppression, facilitating a more effective immune response correlated with decreases in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) level in blood.
“Our study shows that COVID-19 is very much a RANTES disease demonstrating 100 times normal levels of RANTES in these critically ill patients and 5 times normal levels of RANTES even in mild-moderate COVID-19 disease,” said Bruce Patterson, MD, founder of IncelDx and advisor to CytoDen, in the press release. “When RANTES is blocked from binding to CCR5 expressed on immune cells, statistically significant increases of CD8 T-cells were seen as early as 7 days post-therapy. IL-6, which was less consistently elevated than RANTES in these patients was significantly decreased by Day 7.”
Patterson further elaborated on the restoration of immune homeostasis resulting in statistically significant decreases in plasma viral load, a quantitative measure using cell-free cancer technology and reported for the first time in this study, according to the press release.
Leronlimab has been granted a Fast Track designation for 2 potential indications, first as a combination therapy with HAART for HIV-infected patients and second as a treatment for metastatic triple-negative breast cancer. The drug has been in 9 clinical trials in more than 800 people, including meeting its primary endpoints in a pivotal phase 3 trial, in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
REFERENCE
Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients [news release]. Vancouver, Washington; CytoDen: May 5, 2020. https://www.cytodyn.com/newsroom/press-releases/detail/426/manuscript-describes-how-cytodyns-leronlimab-disrupts. Accessed May 6, 2020.
Novel Drug May Reduce Inflammation in Critical COVID-19 Patients
2020-05-12 13:39:00
Jill Murphy, Assistant Editor
A pre-print version of a manuscript about the development of leronlimab describes the immunological mechanism by which leronlimab restores immune function and impacts the coronavirus disease 2019 (COVID-19), according to a CytoDen press release.
The manuscript, entitled “Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19,” has been submitted for publication and is currently under peer review.
The pre-print describes a cohort of 10 critically ill patients after treatment with leronlimab who experienced reversed hyper immune activation and inflammation, as well as reversed immunosuppression, facilitating a more effective immune response correlated with decreases in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) level in blood.
“Our study shows that COVID-19 is very much a RANTES disease demonstrating 100 times normal levels of RANTES in these critically ill patients and 5 times normal levels of RANTES even in mild-moderate COVID-19 disease,” said Bruce Patterson, MD, founder of IncelDx and advisor to CytoDen, in the press release. “When RANTES is blocked from binding to CCR5 expressed on immune cells, statistically significant increases of CD8 T-cells were seen as early as 7 days post-therapy. IL-6, which was less consistently elevated than RANTES in these patients was significantly decreased by Day 7.”
Patterson further elaborated on the restoration of immune homeostasis resulting in statistically significant decreases in plasma viral load, a quantitative measure using cell-free cancer technology and reported for the first time in this study, according to the press release.
Leronlimab has been granted a Fast Track designation for 2 potential indications, first as a combination therapy with HAART for HIV-infected patients and second as a treatment for metastatic triple-negative breast cancer. The drug has been in 9 clinical trials in more than 800 people, including meeting its primary endpoints in a pivotal phase 3 trial, in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
REFERENCE
Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients [news release]. Vancouver, Washington; CytoDen: May 5, 2020. https://www.cytodyn.com/newsroom/press-releases/detail/426/manuscript-describes-how-cytodyns-leronlimab-disrupts. Accessed May 6, 2020.
Oh, they got a lotta stuff in that bill. You didn't think they would just send us money without writing in a ton of other giveaways.
https://www.yahoo.com/gma/house-democrats-unveil-3t-relief-bill-aid-states-193100797.html
Last edited by a moderator:
cosjobs
Footballguy
From Fox News
Experimental coronavirus treatment leronlimab has delivered “strong results” in the treatment of COVID-19 patients, according to developer CytoDyn.
In a statement released Thursday, CytoDyn cited results from patients treated under the FDA’s Emergency Investigational New Drug (EIND) program. The majority of patients, it said, have had “remarkable recoveries.”
Leronlimab is a viral-entry inhibitor that has targeted HIV and breast cancer. The drug also has been attracting attention as a potential coronavirus treatment, particularly to quell the so-called “cytokine storm,” when COVID-19 has caused the immune system to go awry.
Some 49 COVID-19 patients have been treated with leronlimab under the program, according to CytoDyn’s statement, including 11 patients in a New York hospital. All of the treated patients were in intensive care because of acute respiratory failure and eight had been placed on mechanical ventilation. Some seven of the patients were organ transplant recipients so they were on immunosuppressive treatment and 10 were on dialysis. One patient was not placed on mechanical ventilation because of a history of lung cancer and lung surgery.
“Despite their pre-existing and severe conditions, we believe we were able to save the lives of four patients,” CytoDyn said. “All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients.”
Some 23 patients were also treated at a Southern California hospital, six of whom were in critical condition, requiring ventilation, and 17 were severely ill, requiring oxygen support.
No death was reported, according to the biotech. “Out of 6 critical patients, all were intubated patients, 3 were extubated (taken off ventilator), 2 patients remain relatively stable and still breathing with the assistance of a ventilator and one patient has shown deterioration in respiratory parameters,” it said.
Of the 17 patients in severe, but not critical, condition, 11 showed respiratory improvement and 8 were discharged from hospital. The recovery of one patient, Samantha Mottet, has been described in a number of media reports. Of the other patients, two remain relatively stable, two were taken off a ventilator and one is on a ventilator, but improving, according to CytoDyn.
Additionally, three intensive care patients in a Georgia hospital were also treated with leronlimab, two of whom were taken off a ventilator. In its statement, CytoDyn said that one patient remains on a ventilator, but is improving.
A patient at another New York hospital was taken off oxygen and discharged from hospital after receiving treatment with leronlimab. CytoDyn also noted that a patient at a Northern California hospital is “now weaning from ventilator and transferred to rehabilitation hospital.”
The Vancouver, Washington-based company said that updates are pending for 10 other patients and five additional patients have been approved to receive leronlimab under the FDA EIND program.
“We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing,” said CytoDyn CEO Nader Pourhassan, in the statement. “The enrollment for our Phase 2 double-blind and Phase 2b/3 trials is moving along rapidly and we believe the results from both studies will be very powerful due to the mechanism of action (MOA) of affecting the viral load and restoring the immune system.”
Earlier this week, CytoDyn released data from a small group of patients showing that the drug reduced the plasma viral load and restored the immune system of COVID-19 patients.
Leronlimab has been one of multiple drugs in the spotlight as the world scrambled to contain the coronavirus pandemic. Many experts, however, have warned that people should not take drugs unless a doctor prescribes them.
CytoDyn recently announced leronlimab had shown a “very promising” response in COVID-19 patients with mild-to-moderate symptoms.
Experimental coronavirus treatment leronlimab has delivered “strong results” in the treatment of COVID-19 patients, according to developer CytoDyn.
In a statement released Thursday, CytoDyn cited results from patients treated under the FDA’s Emergency Investigational New Drug (EIND) program. The majority of patients, it said, have had “remarkable recoveries.”
Leronlimab is a viral-entry inhibitor that has targeted HIV and breast cancer. The drug also has been attracting attention as a potential coronavirus treatment, particularly to quell the so-called “cytokine storm,” when COVID-19 has caused the immune system to go awry.
Some 49 COVID-19 patients have been treated with leronlimab under the program, according to CytoDyn’s statement, including 11 patients in a New York hospital. All of the treated patients were in intensive care because of acute respiratory failure and eight had been placed on mechanical ventilation. Some seven of the patients were organ transplant recipients so they were on immunosuppressive treatment and 10 were on dialysis. One patient was not placed on mechanical ventilation because of a history of lung cancer and lung surgery.
“Despite their pre-existing and severe conditions, we believe we were able to save the lives of four patients,” CytoDyn said. “All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients.”
Some 23 patients were also treated at a Southern California hospital, six of whom were in critical condition, requiring ventilation, and 17 were severely ill, requiring oxygen support.
No death was reported, according to the biotech. “Out of 6 critical patients, all were intubated patients, 3 were extubated (taken off ventilator), 2 patients remain relatively stable and still breathing with the assistance of a ventilator and one patient has shown deterioration in respiratory parameters,” it said.
Of the 17 patients in severe, but not critical, condition, 11 showed respiratory improvement and 8 were discharged from hospital. The recovery of one patient, Samantha Mottet, has been described in a number of media reports. Of the other patients, two remain relatively stable, two were taken off a ventilator and one is on a ventilator, but improving, according to CytoDyn.
Additionally, three intensive care patients in a Georgia hospital were also treated with leronlimab, two of whom were taken off a ventilator. In its statement, CytoDyn said that one patient remains on a ventilator, but is improving.
A patient at another New York hospital was taken off oxygen and discharged from hospital after receiving treatment with leronlimab. CytoDyn also noted that a patient at a Northern California hospital is “now weaning from ventilator and transferred to rehabilitation hospital.”
The Vancouver, Washington-based company said that updates are pending for 10 other patients and five additional patients have been approved to receive leronlimab under the FDA EIND program.
“We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing,” said CytoDyn CEO Nader Pourhassan, in the statement. “The enrollment for our Phase 2 double-blind and Phase 2b/3 trials is moving along rapidly and we believe the results from both studies will be very powerful due to the mechanism of action (MOA) of affecting the viral load and restoring the immune system.”
Earlier this week, CytoDyn released data from a small group of patients showing that the drug reduced the plasma viral load and restored the immune system of COVID-19 patients.
Leronlimab has been one of multiple drugs in the spotlight as the world scrambled to contain the coronavirus pandemic. Many experts, however, have warned that people should not take drugs unless a doctor prescribes them.
CytoDyn recently announced leronlimab had shown a “very promising” response in COVID-19 patients with mild-to-moderate symptoms.
Bossman
Footballguy
Good luck!
This guy gets it.
These opportunities don't come around that often. Almost seems like someone made a mistake? Nothing not to like with this play.
Man In The Box
Footballguy
You guys all need to hit the streets with your CYDY for Covid signs. We need an effective treatment. Badly.
TripItUp
Footballguy
Agreed, good find. My order to sell the $7.50 puts did not hit before the close. Hoping it opens lower, the puts go up in premium and I jump on board tomorrow morning.
ghostguy123
Footballguy
TripItUp
Footballguy
Not all hotels...Marriott in particular.
Well capitalized.
Well run.
Will have long term benefit from ma and pa hotels going under and will increase market share.
Marriott currently trading in the 70s when it was at 141 not too long ago...nearly half.
There probably isn't a rush because there will be a correlation with a vaccine/treatment and increased travel, but there are some indicators in China and elsewhere that travel will bounce back some in the near term. I'd prefer to get in now and expect a 30% gain within a year. Close to 100% at 2 years...conservatively. Note that this is an opinion and a forecast.
Last edited by a moderator:
sporthenry
Footballguy
So what does the crystal ball say about today's move? Seems like something wasn't priced in? Or the markets looking 9 months out and saw a bad winter storm?
I’ve traded in and out of Marriott like it’s a blooming onion. It’s definitely on my radar. Still holding a few shares at $59. Sold the bulk at $86
Jefferson the Caregiver
Rebel Without A Pause
Good that they are getting press, just don't like that its basically just a retweet of their own press releases though. Want to see something more than what Cytodyn thinks of their own results.cosjobs said:
More Otto Yang and hopefully some new Doctors too, Less NP
metoo
Footballguy
Fidelity has probably made about 5 million off of you and Cos because of this.
They are making money off of the trade.
sporthenry
Footballguy
It's almost like someone forgot to code the overnight algos with sell orders.
Betterbelieveit
Footballguy
OK I'm in. I like some of the advice and this seems like a no brainer. So how do you find these niche moves? Strategy seems right just not sure you can find this value consistently. But I'll take this one for sure. Also have been on the CYDY train for awhile. Thanks to all for your input.Bossman said:
matuski
Footballguy
Don Hutson
Footballguy
Don Hutson
Footballguy
Dr Yo's new video:
Right now, 85% of all corona workers comp claims are 0 dollars, 12% are under 10k and 3% over 10k. Aig already took a charge to 1st q for corona. The big insurance companies are well insulated ( surplus and reinsurance) to cat related occurrences.
Bossman
Footballguy
You find these niche moves by reading FBG Stock thread and looking for posts from Bossman.
j/k ... You don't find this kind this move. They typically do not exist. This one (NERV) is a vein of gold in a giant rock quarry.
TDA has a Think or Swim app that is helpful. Put in your parameters and poke around.
You can find some that are pretty juicy ... and then do the research as to why ... bankruptcy looming etc.
I'm sure there are other tools to find option % if you look for them.
Last edited by a moderator:
GoBirds
Footballguy
Never mind, posted above. It’s a tiny fee.You are getting hosed, Vanguard doesn’t charge me anything.
Last edited by a moderator:
I know the market has everything priced in and is forward looking, but I’ve been legitimately surprised at how much a good Q1 has mattered. I wasn’t wearing a mask going to Costco in mid March and NC wasn’t really shut down (schools and non-essentials) until the last two weeks of March. My company was early on the work from home and that started on March 9th (Disney World was March 16th). You’re talking about 2.5 of the 3 months of Q1 not really being affected. I know the huge gains (like TWLO, DDOG and FSLY for me) were from reports that mentioned Q2 being better than expected but Q2 numbers in general are going to be way worse. I think the market could be OK for a bit unless we keep hearing about shutdown extensions and end of July when the gruesome earnings reports start.
cosjobs
Footballguy
Yeah, what I liked most is that FOX probably reaches more folks than most all the others combined. It will help with brand and product recognition
